Brooks Laboratories Ltd
NSE:BROOKS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Brooks Laboratories Ltd
Cash from Operating Activities
Brooks Laboratories Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brooks Laboratories Ltd
NSE:BROOKS
|
Cash from Operating Activities
₹39.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Cash from Operating Activities
₹23.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Cash from Operating Activities
₹9.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Cash from Operating Activities
-₹678.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Cash from Operating Activities
₹3.1B
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Cash from Operating Activities
₹4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Brooks Laboratories Ltd
Glance View
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
See Also
What is Brooks Laboratories Ltd's Cash from Operating Activities?
Cash from Operating Activities
39.4m
INR
Based on the financial report for Dec 31, 2025, Brooks Laboratories Ltd's Cash from Operating Activities amounts to 39.4m INR.
